These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 7733108)

  • 21. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus.
    Umansky M; Yasui W; Hallak A; Brill S; Shapira I; Halpern Z; Hibshoosh H; Rattan J; Meltzer S; Tahara E; Arber N
    Oncogene; 2001 Nov; 20(55):7987-91. PubMed ID: 11753681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
    Wheeldon TU; Granström M; Hoang TT; Phuncarg DC; Nilsson LE; Sörberg M
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1315-21. PubMed ID: 15191514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
    Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
    Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
    Müller P; Fuchs W; Peifer-Weiss A; Simon B
    Fortschr Med; 1998 Oct; 116(28):31-2. PubMed ID: 9844264
    [No Abstract]   [Full Text] [Related]  

  • 25. Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen.
    Nagahara A; Miwa H; Kawabe M; Kurosawa A; Asaoka D; Hojo M; Iijima K; Terai T; Ohkusa T; Miyazaki A; Sato N
    J Gastroenterol; 2004 Nov; 39(11):1051-5. PubMed ID: 15580397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH.
    Pais SA; Nathwani RA; Dhar V; Nowain A; Laine L
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1607-13. PubMed ID: 16696810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression.
    Kahaleh M; Van Laethem JL; Nagy N; Cremer M; Devière J
    Endoscopy; 2002 Dec; 34(12):950-5. PubMed ID: 12471537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Results of pre- and postoperative treatment of complicated duodenal ulcers with proton pump inhibitors ].
    Cherniakevich SA; Babkova IV; Mikhalev AI
    Klin Med (Mosk); 2002; 80(9):52-4. PubMed ID: 12416227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is lansoprazole (Prevacid) or omeprazole (Prilosec) more effective in treating erosive esophagitis?
    Kim JD
    J Fam Pract; 2002 Apr; 51(4):384. PubMed ID: 11978268
    [No Abstract]   [Full Text] [Related]  

  • 30. Asymptomatic giardiasis--an association with proton pump inhibitors?
    Mukherjee S
    Am J Gastroenterol; 2000 Dec; 95(12):3666-7. PubMed ID: 11151928
    [No Abstract]   [Full Text] [Related]  

  • 31. Importance of adequate acid suppression in the management of Barrett's esophagus.
    Castell DO; Katzka DA
    Gastroenterology; 1999 Dec; 117(6):1509-10. PubMed ID: 10610344
    [No Abstract]   [Full Text] [Related]  

  • 32. ["Changing of the guard" in the inhibition of proton pumps?].
    Internist (Berl); 1998 Oct; 39(10 Suppl Wachablosu):1-8. PubMed ID: 9810869
    [No Abstract]   [Full Text] [Related]  

  • 33. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy.
    Wilkinson SP; Biddlestone L; Gore S; Shepherd NA
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1205-9. PubMed ID: 10468702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Healing of esophageal ulcer after treatment with omeprazole in a patient with scleroderma and Barrett's esophagus].
    Fiorucci S; Santucci L; Bassotti G; Pelli MA; Morelli A
    Medicina (Firenze); 1988; 8(3):306-9. PubMed ID: 3231041
    [No Abstract]   [Full Text] [Related]  

  • 35. [Drug UDCA (Ursosan) in therapeutic management of patients Barrett's esophagus].
    Onuchina EV; Tsukanov VV; Osipenko MF
    Eksp Klin Gastroenterol; 2010; (12):96-101. PubMed ID: 21560631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a proton-pump inhibitor for metabolic disturbances associated with anorexia nervosa.
    Eiro M; Katoh T; Watanabe T
    N Engl J Med; 2002 Jan; 346(2):140. PubMed ID: 11784888
    [No Abstract]   [Full Text] [Related]  

  • 37. Alternative method for administering proton-pump inhibitors through nasogastric tubes.
    Peckman HJ
    Am J Health Syst Pharm; 1999 May; 56(10):1020. PubMed ID: 10365730
    [No Abstract]   [Full Text] [Related]  

  • 38. A new method of endoscopic treatment for Barrett's esophagus.
    Wang KK; Song MW
    Gastrointest Endosc; 1996 Nov; 44(5):627-9. PubMed ID: 8934180
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube.
    Messaouik D; Sautou-Miranda V; Bagel-Boithias S; Chopineau J
    Int J Pharm; 2005 Aug; 299(1-2):65-72. PubMed ID: 15990258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
    Jankowski J; Moayyedi P
    J Natl Cancer Inst; 2004 Jun; 96(11):885-7; author reply 887. PubMed ID: 15173278
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.